STOCK TITAN

ALLURION TECHNOLOGIES INC - ALUR STOCK NEWS

Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.

Overview of Allurion Technologies Inc

Allurion Technologies Inc is a specialized medical device company focused on providing a non-invasive weight loss platform that combines cutting-edge technology with a unique procedure-less approach. The company has engineered a revolutionary weight management system based on a swallowable intragastric balloon that is administered under the guidance of healthcare professionals without the need for surgery, endoscopy, or anesthesia.

Core Business and Value Proposition

The foundation of Allurion's offering is its proprietary intragastric balloon—a capsule that, once swallowed, provides a temporary space-occupying mechanism in the stomach to help patients achieve satiety and reduce overall caloric intake. This innovative device is seamlessly integrated with a digital care platform that includes AI-powered remote patient monitoring tools, secure messaging, and telehealth consultations. Such integration enables physicians to track patient progress, manage interventions remotely, and deliver personalized behavioral modification guidance. This dual-pronged approach not only enhances patient safety and convenience but also supports a sustained behavior change that is essential for long-term weight management.

Technology and Digital Integration

The Allurion Program represents a significant leap in the application of medical devices within the digital health sphere. By leveraging AI algorithms and sophisticated telehealth networks, the platform provides robust, real-time patient monitoring. This ensures that patients receive timely support and that any deviations in their weight loss journey are promptly addressed. The system encapsulates modern digital trends such as remote patient engagement, virtual consultations, and data-driven insights, positioning it at the forefront of technology-enabled healthcare solutions.

Operational Model and Market Position

Allurion Technologies operates within the competitive landscape of obesity management and medical weight loss solutions. Its business model centers on delivering a comprehensive, tech-enabled healthcare approach that integrates a one-time device usage with ongoing digital support services. This model allows the company to appeal to a wide range of patients who are seeking effective, non-surgical weight loss interventions. The procedure-less nature of the intragastric balloon reduces the risks and recovery time traditionally associated with invasive weight loss surgeries, making it an attractive option for healthcare providers and patients alike.

Industry Relevance and Competitive Advantages

Within the healthcare and medical device industry, Allurion is recognized for its innovative solution that addresses the prevalent need for safe and effective weight management techniques. Its unique blend of a physical device and a connected digital support system provides a comprehensive approach to weight loss that distinguishes it from both traditional bariatric procedures and emerging non-invasive alternatives. The company's commitment to integrating digital monitoring with clinical guidance builds trust among healthcare professionals and patients, underlining the effectiveness of its weight management methodology.

Benefits for Patients and Healthcare Providers

Patients benefit from an accessible, non-invasive treatment option that does not require the risks associated with surgery. The system's integrated remote monitoring not only promotes consistent patient engagement but also facilitates early detection of potential issues. Healthcare providers are supported by a streamlined process that includes secure patient communication, actionable health data, and the ability to provide tailored behavioral counseling. These features collectively enhance patient outcomes and support a rigorous clinical process that is both scalable and efficient.

Commitment to Quality and Safety

Allurion Technologies emphasizes rigorous clinical protocols and continuous improvements in device design and digital support mechanisms. The procedure-less approach reduces the barriers to treatment and provides a safer alternative to invasive surgeries. Through relentless innovation and adherence to stringent quality standards, the company maintains trust with both patients and healthcare providers, reinforcing its reputation as a reliable player in the field of non-invasive weight loss solutions.

Conclusion

Allurion Technologies Inc stands out as a comprehensive, technology-driven solution provider in the obesity management space. With its innovative swallowed intragastric balloon and integrated digital health platform, the company offers a distinctive, non-invasive alternative to traditional weight loss treatments. Its emphasis on combining physical device efficacy with the benefits of AI-supported patient monitoring and telehealth consultations underlines its commitment to delivering impactful, patient-centric healthcare solutions.

Rhea-AI Summary

Allurion Technologies, Inc. (NYSE: ALUR) announced three scientific presentations at IFSO-European Chapter 2024, highlighting 80% sustained weight loss at three years with the Allurion Program and successful outcomes of an AI-powered conversational agent for obesity treatment. The data showcased positive long-term weight maintenance results and patients' healthier eating habits post-program. Additionally, the innovative AI-powered weight loss coach, Coach Iris, received positive feedback for its personalized, trustworthy, and empathetic approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
none
-
Rhea-AI Summary

Allurion Technologies, Inc. announced preliminary first quarter 2024 results, with quarter-over-quarter revenue growth, procedural volume growth, and a significant decrease in cash burn. The company expects revenue between $9.2 million to $9.3 million, 12%-13% higher than the fourth quarter of 2023, procedural volume growth of 22%, and reduced cash burn of $8 million to $9 million. Allurion remains optimistic about future growth and business opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) closes a $48 million convertible senior secured note financing with RTW Investments, reducing interest expenses, extending cash runway, and strengthening the partnership. The transaction simplifies the capital structure, lowers the interest rate to 6%, and extends the maturity of the debt. The funding will be used to repay existing term loans, providing operational flexibility and enhancing future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
none
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) announces the commercial availability of its Virtual Care Suite (VCS) in the United States, a comprehensive weight-loss management suite powered by AI. The VCS aims to enhance patient outcomes and satisfaction through remote patient monitoring, telehealth, and care team collaboration. The addition of Coach Iris, a 24/7 AI-powered weight loss coach, further personalizes the behavior change program. The VCS has shown to improve patient results, engagement, and satisfaction, with clinics experiencing an additional 11% weight loss and a 17% increase in Net Promoter Score (NPS). Allurion will showcase the VCS at the Obesity Medicine Conference in Denver on April 25, introducing a new version of Allurion Insights, the web-based dashboard for providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.03%
Tags
none
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) reported Q4 revenue of $8.2 million and full-year 2023 revenue of $53.5 million, reiterating 2024 guidance. The company completed enrollment in the AUDACITY pivotal trial ahead of schedule, conducted research on healthcare professionals and patients, and treated the first UK NHS-reimbursed patients with the Allurion Balloon. Despite macroeconomic challenges, Allurion saw a 30% increase in procedural volume. The company expects 2024 revenue of $60-65 million, gross margins of 77-79%, and a cash burn of $30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on March 12 - 13, 2024. The company's CEO and CFO will present at the event, with a live webcast available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
conferences
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will report Q4 2023 financial results on March 21, 2024. A conference call will follow to discuss results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
conferences earnings
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) to participate in the 44th Annual Cowen Health Care Conference. CEO and CFO to present on March 5, 2024, at 9:50 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) will be participating in the BTIG Snowbird Conference from February 12-14, 2024. CEO Shantanu Gaur and CFO Chris Geberth will be available for investor 1x1 meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE:ALUR) has appointed Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan brings 20 years of experience as a legal and compliance officer at public companies, with his most recent role at Acushnet Company. In this new role, Brendan will lead the company’s legal and compliance strategies, guiding its global expansion and commitment to delivering safe and effective weight loss solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none

FAQ

What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?

The current stock price of ALLURION TECHNOLOGIES (ALUR) is $3.21 as of March 31, 2025.

What is the market cap of ALLURION TECHNOLOGIES (ALUR)?

The market cap of ALLURION TECHNOLOGIES (ALUR) is approximately 18.3M.

What is the core focus of Allurion Technologies Inc?

Allurion Technologies Inc specializes in a non-invasive weight loss platform that combines a swallowable intragastric balloon with a suite of digital health tools, including AI-powered remote monitoring and telehealth services.

How does the Allurion Program work?

The Allurion Program utilizes a capsule-based intragastric balloon that is swallowed and deployed without surgery, coupled with digital support for patient monitoring and behavioral guidance, all under healthcare provider supervision.

What distinguishes Allurion's weight loss solution from traditional methods?

Unlike traditional surgical options, Allurion's solution is procedure-less and non-invasive, minimizing patient risk and recovery time while leveraging integrated digital tools for continuous care and support.

Who can benefit from Allurion's weight loss platform?

The platform is designed for overweight individuals seeking a medically supervised, non-surgical weight loss solution, and is recommended by healthcare professionals for safe and effective weight management.

How is advanced technology integrated into Allurion's services?

Allurion integrates AI-powered remote monitoring, secure messaging, and telehealth consultations into its weight loss platform, ensuring real-time patient support and personalized behavioral interventions.

How does Allurion maintain trust and safety in its offerings?

The company emphasizes robust clinical protocols, rigorous quality control, and continuous technological enhancements, ensuring that both patients and healthcare providers can trust the efficacy and safety of its non-invasive weight loss solution.
ALLURION TECHNOLOGIES INC

NYSE:ALUR

ALUR Rankings

ALUR Stock Data

18.31M
5.10M
13.85%
22.25%
2.11%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NATICK